Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.200
+0.060 (5.26%)
At close: Sep 5, 2025, 4:00 PM
1.230
+0.030 (2.50%)
After-hours: Sep 5, 2025, 4:10 PM EDT

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
77----
Upgrade
Gross Profit
77----
Upgrade
Selling, General & Admin
26.3328.7228.8830.6526.9610.59
Upgrade
Research & Development
115.68118103.3992.8986.7848.18
Upgrade
Operating Expenses
142.01146.71132.28123.54113.7458.76
Upgrade
Operating Income
-135.01-139.71-132.28-123.54-113.74-58.76
Upgrade
Other Non Operating Income (Expenses)
10.6912.5410.458.12.041.83
Upgrade
Pretax Income
-124.32-127.17-121.83-115.44-111.69-56.93
Upgrade
Net Income
-124.32-127.17-121.83-115.44-111.69-56.93
Upgrade
Net Income to Common
-124.32-127.17-121.83-115.44-111.69-56.93
Upgrade
Shares Outstanding (Basic)
767660474612
Upgrade
Shares Outstanding (Diluted)
767660474612
Upgrade
Shares Change (YoY)
5.12%25.60%27.41%2.87%269.03%647.86%
Upgrade
EPS (Basic)
-1.64-1.68-2.02-2.44-2.43-4.56
Upgrade
EPS (Diluted)
-1.64-1.68-2.02-2.44-2.43-4.56
Upgrade
Free Cash Flow
-108.53-103.65-110.58-86.75-85.85-46.8
Upgrade
Free Cash Flow Per Share
-1.43-1.37-1.83-1.83-1.86-3.75
Upgrade
Gross Margin
100.00%100.00%----
Upgrade
Operating Margin
-1928.67%-1995.91%----
Upgrade
Profit Margin
-1775.97%-1816.76%----
Upgrade
Free Cash Flow Margin
-1550.41%-1480.74%----
Upgrade
EBITDA
-133.25-137.94-131.11-122.22-112.82-58.22
Upgrade
D&A For EBITDA
1.761.771.171.320.920.54
Upgrade
EBIT
-135.01-139.71-132.28-123.54-113.74-58.76
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q